Drug
Pd-132301 hydrochloride clinical trials
Also written ATR-101 and Nevanimibe hydrochloride.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2013
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2013 (1)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 0
Millendo Therapeutics, Inc. (2) · Millendo Therapeutics US, Inc. (2)
Studies
Open first, then newest update. How each study uses pd-132301 hydrochloride is read from its arms, and is right about nine times in ten.
Testing it · 4
- A Study of ATR-101 for the Treatment of Congenital Adrenal HyperplasiaCompletedPhase 2Millendo Therapeutics, Inc.NCT02804178Written as ATR-101
- Nevanimibe HCl for the Treatment of Classic CAHTerminatedPhase 2Millendo Therapeutics US, Inc.NCT03669549Written as Nevanimibe hydrochloride
- A Study of ATR-101 for the Treatment of Endogenous Cushing's SyndromeTerminatedPhase 2Millendo Therapeutics US, Inc.NCT03053271Written as ATR-101
- Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical CarcinomaCompletedPhase 1Millendo Therapeutics, Inc.NCT01898715Written as ATR-101
Codes
What other systems call pd-132301 hydrochloride · ClinicalTrials.gg INT003705
- UNII (FDA) TK694ZFS57NEVANIMIBE HYDROCHLORIDEConfirmed FDA, NLM, Wikidata
- Wikidata Q27289998pd-132301 hydrochlorideConfirmed FDA, NLM, Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | TK694ZFS57 | NEVANIMIBE HYDROCHLORIDE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27289998 | pd-132301 hydrochloride | Confirmed FDA, NLM, Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.